Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment (Review)
- Authors:
- Dehua Zhao
- Jing Chen
- Xiaoqing Long
- Jisheng Wang
-
Affiliations: Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan 621000, P.R. China - Published online on: November 27, 2020 https://doi.org/10.3892/or.2020.7870
- Pages: 413-426
-
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–403. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI | |
|
Sgambato A, Casaluce F, Maione P and Gridelli C: Targeted therapies in non-small cell lung cancer: A focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 18:71–80. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DH: Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. Pharmacol Ther. 174:1–21. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, et al: NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 17:1464–1472. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar | |
|
Holleman MS, van Tinteren H, Groen HJ, Al MJ and Uyl-de Groot CA: First-line Tyrosine Kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: A network meta-analysis. Onco Targets Ther. 12:1413–1421. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Verbeeck RK: Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 64:1147–1161. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Verbeeck RK and Musuamba FT: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 65:757–773. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdfFeb 2–2020 | |
|
Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N and Yu L: Effect of hepatic impairment on the pharmacokinetics of alectinib. J Clin Pharmacol. 58:1618–1628. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208772s004lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203756s008lbl.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s007lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/cometriq-epar-product-information_en-0.pdfFeb 2–2020 | |
|
Nguyen L, Chapel S, Tran BD and Lacy S: Updated population pharmacokinetic model of cabozantinib integrating various cancer types including hepatocellular carcinoma. J Clin Pharmacol. 59:1551–1561. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen L, Holland J, Ramies D, Mamelok R, Benrimoh N, Ciric S, Marbury T, Preston RA, Heuman DM, Gavis E and Lacy S: Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 56:1130–1140. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205755s016lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdfFeb 2–2020 | |
|
El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T and El-Rayes BF: Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 81:659–670. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdfFeb 2–2020 | |
|
Ouellet D, Gibiansky E, Leonowens C, O'Hagan A, Haney P, Switzky J and Goodman VL: Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol. 54:696–706. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdfFeb 2–2020 | |
|
Giri N, Masters JC, Plotka A, Liang Y, Boutros T, Pardo P, O'Connell J and Bello C: Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs. 33:931–941. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdfMay 3–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdfFeb 2–2020 | |
|
O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, et al: An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 69:605–612. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, et al: Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 25:3055–3060. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/gefitinib-mylan-epar-product-information_en.pdfFeb 2–2020 | |
|
Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H and Twelves C: The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol. 68:1485–1495. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdfFeb 2–2020 | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdfFeb 2–2020 | |
|
Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M and Vishwanathan K: Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment. J Pharmacol Exp Ther. 369:291–299. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s014lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdfFeb 2–2020 | |
|
Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, DeMarini DJ, Gardner O, Crist W and Patel K: Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 77:807–817. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022405s014lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdfFeb 2–2020 | |
|
Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J and Molz KH: Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet. 49:607–618. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
US Food and Drug Administration. Label, . simplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdfFeb 2–2020 | |
|
European Medicines Agency. Product information, . simplehttps://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdfFeb 2–2020 | |
|
Zhang W, Heinzmann D and Grippo JF: Clinical pharmacokinetics of vemurafenib. Clin Pharmacokinet. 56:1033–1043. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Field KM and Michael M: Part II: Liver function in oncology: Towards safer chemotherapy use. Lancet Oncol. 9:1181–1190. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Krens SD, Lassche G, Jansman FG, Desar IM, Lankheet NA, Burger DM, van Herpen CM and van Erp NP: Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 20:e200–e207. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pond SM and Tozer TN: First-pass elimination: Basic concepts and clinical consequences. Clin Pharmacokinet. 9:1–25. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Chtioui H and Buclin T: Pharmacokinetics in hepatic impairment: Mind the protein binding. J Hepatol. 63:1539–1540. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Villeneuve JP and Pichette V: Cytochrome P450 and liver diseases. Curr Drug Metab. 5:273–282. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H and Trauner M: Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 38:717–727. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Proulx NL, Akbari A, Garg AX, Rostom A, Jaffey J and Clark HD: Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: A Systematic review and individual patient Meta-analysis. Nephrol Dial Transplant. 20:1617–1622. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
European Medicines Agency, . Guideline on the evalution of the pharmacokinetics of medicinal products in patients with impaired hepatic function. simplehttps://www.ema.europa.eu/documents/scientific-guideline/guideline-evaluation-pharmacokineticsmedicinal-products-patients-impaired-hepatic-function_en.pdfJan 20–2020 | |
|
US Food and Drug Administration, . Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling. simplehttps://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdfJan 20–2020 | |
|
Mansfield AS, Rudek MA, Vulih D, Smith GL, Harris PJ and Ivy SP; NCI Organ Dysfunction Working Group, : The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects. Clin Cancer Res. 22:5472–5479. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M and Kato Yo: Decreased disposition of anticancer drugs predominantly eliminated via the liver in patients with renal failure. Curr Drug Metab. 20:361–376. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim AH, Yoon S, Lee Y, Lee J, Bae E, Lee H, Kim DK, Lee S, Yu KS, Jang IJ and Cho JY: Assessment of Hepatic Cytochrome P450 3A activity using metabolic markers in patients with renal impairment. J Korean Med Sci. 33:e2982018. View Article : Google Scholar : PubMed/NCBI | |
|
Matzke GR, Dowling TC, Marks SA and Murphy JE: Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. J Clin Pharmacol. 56:390–398. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A and Wind S: Influence of renal impairment on the pharmacokinetics of afatinib: An Open-Label, Single-Dose Study. Eur J Drug Metab Pharmacokinet. 42:461–469. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M and Feldman HI: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 63:713–735. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shah RR and Shah DR: Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 42:181–198. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Imai H, Kaira K, Naruse I, Hayashi H, Iihara H, Kita Y, Mizusaki N, Asao T, Itoh Y, Sugiyama T, et al: Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemother Pharmacol. 79:209–213. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bersanelli M, Tiseo M, Artioli F, Lucchi L and Ardizzoni A: Gefitinib and Afatinib treatment in an advanced Non-small cell lung cancer (NSCLC) Patient Undergoing Hemodialysis. Anticancer Res. 34:3185–3188. 2014.PubMed/NCBI | |
|
Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K and Nakagawa K: Safety and Efficacy of alectinib in a patient with advanced NSCLC Undergoing Hemodialysis. J Thorac Oncol. 14:e50–e52. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hong Y, Passos VQ, Huang PH and Lau YY: Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. J Clin Pharmacol. 57:652–662. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tan W, Yamazaki S, Johnson TR, Wang R, O'Gorman MT, Kirkovsky L, Boutros T, Brega NM and Bello A: Effects of renal function on crizotinib pharmacokinetics: Dose recommendations for patients with ALK-Positive Non-Small cell lung cancer. Clin Drug Investig. 37:363–373. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang E, Nickens DJ, Bello A, Khosravan R, Amantea M, Wilner KD, Parivar K and Tan W: Clinical implications of the pharmacokinetics of crizotinib in populations of patients with non-small cell lung cancer. Clin Cancer Res. 22:5722–5728. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kothari S, Ud-Din N, Lisi M and Coyle T: Crizotinib in anaplastic lymphoma kinasepositive anaplastic large cell lymphoma in the setting of renal insufficiency: A case report. J Med Case Rep. 10:1762016. View Article : Google Scholar : PubMed/NCBI | |
|
Song SH, Ryu JW, Jwa HY, Ha CW, Kim H, Jo JM and Han SH: ALK-positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis. Thorac Cancer. 10:2188–2191. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Park JJ, Boddy AV, Liu X, Harris D, Lee V, Kefford RF and Carlino MS: Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell Melanoma Res. 30:68–71. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, et al: Pharmacokinetics of Erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol. 5:601–605. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gridelli C, Maione P, Galetta D and Rossi A: Safety profile of Erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J Thorac Oncol. 2:96–98. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V and Gridelli C: Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: Two clinical cases. Lung Cancer. 47:421–423. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi T, Isogai S, Okamura T, Uozu S, Mieno Y, Hoshino T, Goto Y, Hayashi M, Nakanishi T and Imaizumi K: Pharmacokinetics of Gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. Case Rep Oncol. 8:78–82. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Ni L, Wang M, Zhong W, Xiao Y, Zheng K and Hu P: Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis. Thorac Cancer. 7:251–253. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shinagawa N, Yamazaki K, Asahina H, Agata J, Itoh T and Nishimura M: Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer. 58:422–424. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Del Conte A, Minatel E, Schinella D, Baresic T, Basso SM and Lumachi F: Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res. 34:319–322. 2014.PubMed/NCBI | |
|
Yamada H, Satoh H, Hida N, Nakaizumi T, Terashima H and Hizawa N: Osimertinib for an older de novo T790M patient with chronic kidney disease. Geriatr Gerontol Int. 18:503–504. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tamura T, Takagi Y, Okubo H, Yamaguchi S, Kikkawa Y, Hashimoto I, Kaburagi T, Miura M, Satoh H and Hizawa N: Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis. Lung Cancer. 112:225–226. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Iwafuchi Y, Saito I and Narita I: Efficacy and safety of osimertinib in a hemodialysis patient with advanced non-small cell lung cancer. Ther Apher Dial. 21:416–417. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Matsunashi A, Fujimoto D, Hosoya K, Irie K, Fukushima S and Tomii K: Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Invest New Drugs. 38:1192–1195. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Iddawela M, Crook S, George L, Lakkaraju A, Nanayakkara N, Hunt R and Adam WR: Safety and efficacy of Vemurafenib in end stage renal failure. BMC Cancer. 13:5812013. View Article : Google Scholar : PubMed/NCBI | |
|
Porta C, Cosmai L, Gallieni M, Pedrazzoli P and Malberti F: Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 11:354–370. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qian J, Zhang X, Zhang B, Yan B, Wang L, Gu P, Wang W, Wang H and Han B: Tyrosine kinase inhibitor-related hepatotoxicity in patients with advanced lung adenocarcinoma: A real-world retrospective study. Cancer Manag Res. 12:3293–3299. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW and Fishbane SL: Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review. Kidney Int Rep. 2:108–123. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
González J, Quiroga M, Escudero-Vilaplana V, Collado-Borrell R, Herranz-Alonso A and Sanjurjo Sáez M: Posology adjustments of oral antineoplastic agents for special populations: Patients with renal impairment, hepatic impairment and hematologic toxicities. Expert Opin Drug Saf. 17:553–572. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, et al: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated Alk-positive advanced non-small cell lung cancer in the global phase III ALEX Study. J Thorac Oncol. 14:1233–1243. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu V and Ou SH: Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 16:509–514. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, et al: Brigatinib versus Crizotinib in ALK-positive Non-small-cell lung cancer. N Engl J Med. 379:2027–2039. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, et al: Cabozantinib versus Sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The alliance A031203 CABOSUN trial. J Clin Oncol. 35:591–597. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, et al: Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): Updated results from the phase 1, multicentre, open-label ASCEND-1 trial. Lancet Oncol. 17:452–463. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Knispel S, Zimmer L, Kanaki T, Ugurel S, Schadendorf D and Livingstone E: The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Expert Opin Drug Saf. 17:73–87. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 18:1307–1316. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al: Entrectinib in patients with advanced or metastatic NTRK fusionpositive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 21:271–282. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Choi HD and Chang MJ: Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis. PLoS One. 15:e02348182020. View Article : Google Scholar : PubMed/NCBI | |
|
Schacher-Kaufmann S and Pless M: Acute fatal liver toxicity under Erlotinib. Case Rep Oncol. 3:182–188. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hsiue EH, Lee JH, Lin CC and Yang JC: Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 15:993–1000. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, et al: Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: Phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 19:705–714. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, et al: Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20:1691–1701. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Qiu X, Xiao G, Hu H and Lin T: Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS One. 14:e02215752019. View Article : Google Scholar : PubMed/NCBI | |
|
Tsang VH, Robinson BG and Learoyd DL: The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf. 15:1107–1113. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI and Sherman EJ: Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial. Lancet Onco. 17:1272–1282. 2016. View Article : Google Scholar | |
|
Borella E, Poggesi I and Magni P: Prediction of the effect of renal impairment on the pharmacokinetics of new drugs. Clin Pharmacokinet. 57:505–514. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hsueh CH, Hsu V, Zhao P, Zhang L, Giacomini KM and Huang SM: PBPK modeling of the effect of reduced kidney function on the pharmacokinetics of drugs excreted renally by organic anion transporters. Clin Pharmacol Ther. 103:485–492. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Solassol I, Pinguet F and Quantin X: FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 9:6682019. View Article : Google Scholar |
